Curran Simpson Sells 7,624 Shares of REGENXBIO (NASDAQ:RGNX) Stock

Key Points

• CEO Curran Simpson sold 7,624 shares of REGENXBIO at an average price of $10.03, reducing his holdings by 3.12%.
• REGENXBIO reported a quarterly EPS of ($1.38), missing forecasts, with revenues of only $21.36 million against expectations of $40.87 million.
• Analysts have varying ratings on REGENXBIO, with Barclays lowering their price target from $50 to $37, while others maintained a "buy" rating with targets up to $52.

REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) CEO Curran Simpson sold 7,624 shares of REGENXBIO stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $10.03, for a total transaction of $76,468.72. Following the completion of the sale, the chief executive officer directly owned 236,973 shares in the company, valued at $2,376,839.19. This trade represents a 3.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Curran Simpson also recently made the following trade(s):

• On Wednesday, September 10th, Curran Simpson sold 7,734 shares of REGENXBIO stock. The stock was sold at an average price of $10.02, for a total transaction of $77,494.68.

REGENXBIO Trading Up 1.2%

Shares of NASDAQ:RGNX traded up $0.12 during mid-day trading on Wednesday, reaching $9.77. The company had a trading volume of 612,354 shares, compared to its average volume of 901,661. The firm has a market cap of $493.48 million, a price-to-earnings ratio of -2.84 and a beta of 1.17. The company's 50-day moving average price is $8.92 and its 200-day moving average price is $8.51. REGENXBIO Inc. has a one year low of $5.03 and a one year high of $12.22.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing analysts' consensus estimates of ($1.13) by ($0.25). REGENXBIO had a negative net margin of 112.70% and a negative return on equity of 66.95%. The business had revenue of $21.36 million during the quarter, compared to analysts' expectations of $40.87 million. On average, research analysts anticipate that REGENXBIO Inc. will post -4.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Barclays reduced their price objective on shares of REGENXBIO from $50.00 to $37.00 and set an "overweight" rating for the company in a research note on Friday, August 8th. Wall Street Zen lowered shares of REGENXBIO from a "hold" rating to a "strong sell" rating in a research note on Saturday, August 9th. Royal Bank Of Canada reduced their price objective on shares of REGENXBIO from $21.00 to $17.00 and set an "outperform" rating for the company in a research note on Friday, August 8th. HC Wainwright restated a "buy" rating and set a $34.00 price target on shares of REGENXBIO in a research report on Monday, September 8th. Finally, Chardan Capital restated a "buy" rating and set a $52.00 price target on shares of REGENXBIO in a research report on Monday, September 8th. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $28.38.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Pale Fire Capital SE grew its position in REGENXBIO by 7.7% in the second quarter. Pale Fire Capital SE now owns 27,846 shares of the biotechnology company's stock worth $229,000 after acquiring an additional 2,000 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in REGENXBIO by 9.1% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 27,756 shares of the biotechnology company's stock worth $198,000 after acquiring an additional 2,326 shares in the last quarter. ProShare Advisors LLC grew its position in REGENXBIO by 22.4% in the fourth quarter. ProShare Advisors LLC now owns 15,314 shares of the biotechnology company's stock worth $118,000 after acquiring an additional 2,800 shares in the last quarter. Brooklyn Investment Group grew its position in REGENXBIO by 163.7% in the first quarter. Brooklyn Investment Group now owns 5,583 shares of the biotechnology company's stock worth $40,000 after acquiring an additional 3,466 shares in the last quarter. Finally, FNY Investment Advisers LLC purchased a new position in REGENXBIO in the first quarter worth $35,000. 88.08% of the stock is currently owned by hedge funds and other institutional investors.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.